Swiss researchers have revealed that mutations of the TP53 gene harm the prognosis for patients with acute myeloid leukaemia (AML) treated with chimeric antigen receptor (CAR)-T cell therapies. However, in a proof-of-concept study, the Zurich-base...
2 days ago